{"id":1821,"date":"2018-12-31T00:00:39","date_gmt":"2018-12-30T17:00:39","guid":{"rendered":"https:\/\/www.hivnat.org\/en\/?p=1821"},"modified":"2018-12-31T00:00:39","modified_gmt":"2018-12-30T17:00:39","slug":"maintenance-of-switching-from-protease-inhibitor-ritonavir-to-generic-single-tablet-regimen-of-tenofovir-alafenamide-emtricitibine-dolutegravir-in-virologically-suppressed-hiv-infected-adults","status":"publish","type":"post","link":"https:\/\/www.hivnat.org\/en\/studies\/1821\/","title":{"rendered":"Maintenance of switching from Protease Inhibitor\/Ritonavir to generic single tablet regimen of Tenofovir Alafenamide\/Emtricitibine\/Dolutegravir in virologically suppressed HIV-infected adults"},"content":{"rendered":"\n\t\t\t\t\n<p><strong>Project no.:<\/strong> HIV-NAT 256\/SPIRITED (NCT03727152)<\/p>\n\n\n\n<p><strong>Brief\nsummary: <\/strong>The fundamental\nprinciple of regimen switching is to maintain viral suppression without\njeopardizing future treatment options. The reasons to consider regimen\nswitching in the viral suppressed population are to simplify the regimen by\nreducing the pill burden and dosing frequency, to increase the tolerability,\nreduce the adverse effects as well as long-term toxicities, to prevent\ndrug-to-drug interactions and to avoid the dietary requirements.<\/p>\n\n\n\n<p>Generic\nTAF\/E\/D (tenofovir alafenamide 25mg\/emtricitabine 200mg\/dolutegravir 50 mg), a\nsingle-tablet once daily regimen, will be an affordable regimen with the\npotential characteristics such as reduced pill burden, less drug to drug\ninteraction and toxicities. The generic form (Mylan) is recently received the\ntentative approval from the U.S. Food and Drug Administration (FDA) under the\nU.S. President&#8217;s Emergency Plan for AIDS Relief (PEPFAR). Whether\nDTG-containing regimen is a better option than protease inhibitors among\nresource-limited settings during the decisions for second-line treatment\noptions, is needed to be evaluated.\n\nAll participants will be\nswitched from their pre-study ART regimen to a single tablet regimen (STR) of\nTAF\/FTC\/DTG 25\/200\/50mg once daily.\n\n\n\n<\/p>\n\t\t","protected":false},"excerpt":{"rendered":"<p>\t\t\t\tThe fundamental principle of regimen switching is to maintain viral suppression without jeopardizing future treatment options.\t\t<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-1821","post","type-post","status-publish","format-standard","hentry","category-studies"],"_links":{"self":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/1821","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/comments?post=1821"}],"version-history":[{"count":0,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/1821\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/media?parent=1821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/categories?post=1821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/tags?post=1821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}